Ryuta Sakai
Kyoto Prefectural University of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ryuta Sakai.
Journal of Cardiovascular Pharmacology | 1995
Ryuta Sakai; Daisuke Inoue; Kazuya Ishibashi; Miho Inoue; Takeshi Shirayama; Yasuhiro Yamahara; Jun Asayama; Masao Nakagawa
We investigated use-dependent prolongation of interatrial conduction time (IACT) by class I antiar-rhythmic drugs in 16 patients. Changes in IACT at the initiation of atrial pacing were used to evaluate the onset kinetics. We examined recovery kinetics by giving a single extra stimulus with a varying coupling interval after discontinuing train stimulation. Time constants of the onset kinetics were 1.52 ± 0.15/n(fast) and 0.087 ± 0.031/ n(slow) for mexiletine, 0.075 ± 0.015/n for aprindine, 0.078 ± 0.019/n for disopyramide, and 0.050 ± 0.006/n for pilsicainide. The recovery time constants were 203 ± 66 ms for mexiletine, 1,021 ± 162 ms for aprindine, 993 ± 101 ms for disopyramide, and 2,930 ± 569 ms for pilsicainide. Class I antiarrhythmic drugs produced use-dependent IACT prolongation in humans, with characteristic kinetics for each agent similar to that of depression of the maximum upstroke velocity of cardiac action potential (Vmax) reported in in vitro studies.
Journal of Cardiovascular Pharmacology | 1994
Miho Inoue; Daisuke Inoue; Kazuya Ishibashi; Ryuta Sakai; Takeshi Shirayama; Jun Asayama; Masao Nakagawa
The effects of E-4031, a new class III antiarrhythmic agent, on atrial fibrillation threshold (AFT), atrial effective refractory period (ERP), and interatrial conduction time (ACT) were investigated in Langendorff-perfused guinea pig hearts; the results were then compared with those of the class I agents disopyramide, procainamide, lidocaine, and flecainide. Whole guinea pig hearts were perfused with Tyrodes solution containing acetylcholine (ACh 3 x 10(-7) M). The three indexes were measured before and after administration of the test drugs, using right atrial extrastimulus and 50-Hz continuous stimulation. Disopyramide, procainamide, and flecainide (> or = 10(-6) M) significantly increased AFT. Although E-4031 (> or = 3 x 10(-6) M) also increased AFT, this effect was less potent than that observed with the other drugs. E-4031 (> or = 10(-6) M) significantly prolonged ERP, and this prolongation was less pronounced than that observed with disopyramide but similar to that observed with procainamide or flecainide. E-4031 did not affect ACT, and the greatest prolongation of ACT was observed with flecainide. Lidocaine had no effect on any of the indexes. These findings suggest that in guinea pig hearts E-4031 exerts an antifibrillatory effect by prolonging atrial ERP alone, but this effect is less pronounced than that observed with class I drugs, because AFT measured by 50-Hz continuous stimulation is influenced by both ERP and ACT.
International Journal of Cardiology | 1995
Kazuya Ishibashi; Daisuke Inoue; Ryuta Sakai; Miho Inoue; Takeshi Shirayama; Jun Asayama; Masao Nakagawa
The effects of disopyramide on the atrial fibrillation threshold (AFT) in the human atrium were investigated. To evaluate atrial vulnerability, the following electrophysiologic parameters were measured before and after the administration of disopyramide (2 mg/kg) in 12 patients with paroxysmal atrial fibrillation: The right atrial effective refractory period (ERP) and percentage maximum atrial fragmentation (%MAF) were measured by atrial premature stimulation based on a cycle length of 500 ms. The inter-atrial conduction time (ACT) was measured by burst pacing (120/min) for 30 s. AFT was measured by applying a high-frequency (50 Hz) stimulation for 1 s given at the right atrial appendage. AFT was defined as the lowest intensity of electrical current that could induce atrial fibrillation lasting for more than 30 s. Disopyramide significantly reduced %MAF, and prolonged ERP and ACT. AFT was measured in all patients and the mean AFT was 3.1 +/- 1.7 mA. After the administration of disopyramide, AFT significantly increased to 6.1 +/- 3.6 mA. There was a positive correlation between ERP and AFT, and a negative correlation between %MAF and AFT. No correlation was detected between ACT and AFT. In conclusion, disopyramide increased AFT in the human atrium.
Cardiovascular Drugs and Therapy | 1993
Daisuke Inoue; Takeshi Shirayama; Itsuki Omori; Miho Inoue; Ryuta Sakai; Kazuya Ishibashi; Hiroshi Miyazaki; Yasuhiro Yamahara; Tetsuya Tatsumi; Jun Asayama; Masao Nakagawa
SummaryThe electrophysiological effects of flecainide acetate (3×10−6 M) on stretched atrial tissue were investigated using guinea-pig left atrial muscle fibers. Before stretching, the resting membrane potential was not affected by flecainide at 1 Hz, although the overshoot potential (Eov) and the action potential duration at 50% repolarization (APD50) were slightly but significantly decreased by 2±1 mV and 2±1 msec, respectively. The effective refractory period (ERP) was increased by 3±1 msec. The reduction of
Japanese Heart Journal | 1993
Miho Inoue; Daisuke Inoue; Kazuya Ishibashi; Ryuta Sakai; Itsuki Omori; Yasuhiro Yamahara; Jun Asayama; Masao Nakagawa
Japanese Heart Journal | 1993
Yasuhiro Yamahara; Jun Asayama; Takashi Matsumoto; Hiroshi Miyazaki; Tetsuya Tatsumi; Bon Ohta; Ryuta Sakai; Miho Inoue; Daisuke Inoue; Masao Nakagawa
\dot V
Japanese Circulation Journal-english Edition | 2009
Natsuya Keira; Takahisa Sawada; Tetsuya Tatsumi; Takeshi Nakamura; Akiyoshi Matsumuro; Shinzo Kimura; Jun Shiraishi; Noriyuki Kinoshita; Manabu Nishio; Maki Katamura; Ryuta Sakai; Yoshiaki Harada; Yasuhiro Yamahara; Takuya Kuriyama; Koji Shiga; Chihiro Yamada; Makoto Kitamura; Yoshio Kohno; Hajime Miyanaga; Keizo Furukawa; Hiroaki Matsubara
Japanese Circulation Journal-english Edition | 2009
Jun Shiraishi; Yoshio Kohno; Takahisa Sawada; Takashi Okada; Takatomo Shima; Takeshi Nakamura; Keizo Furukawa; Hajime Miyanaga; Makoto Kitamura; Chihiro Yamada; Tetsuya Tatsumi; Takuya Kuriyama; Koji Shiga; Yoshiaki Harada; Yasuhiro Yamahara; Ryuta Sakai; Maki Katamura; Noriyuki Kinoshita; Manabu Nishio; Shinzo Kimura; Hiroaki Matsubara
max was 20.6±1.2%. The half-maximum potential (Vh) of the relationship between
Japanese Circulation Journal-english Edition | 2008
Jun Shiraishi; Yoshio Kohno; Takahisa Sawada; Takashi Okada; Takeshi Nakamura; Keizo Furukawa; Hajime Miyanaga; Makoto Kitamura; Chihiro Yamada; Tetsuya Tatsumi; Takuya Kuriyama; Koji Shiga; Yoshiaki Harada; Yasuhiro Yamahara; Ryuta Sakai; Maki Katamura; Noriyuki Kinoshita; Natsuya Keira; Manabu Nishio; Shinzo Kimura; Hiroaki Matsubara
Japanese Circulation Journal-english Edition | 2007
Jun Shiraishi; Yoshio Kohno; Takatomo Shima; Takahisa Sawada; Tetsuya Tatsumi; Akihiro Azuma; Keizo Furukawa; Hajime Miyanaga; Makoto Kitamura; Chihiro Yamada; Takashi Okada; Takuya Kuriyama; Koji Shiga; Yoshiaki Harada; Yasuhiro Yamahara; Ryuta Sakai; Kazuki Ito; Maki Katamura; Natsuya Keira; Kazuto Yamamoto; Hiroaki Matsubara
\dot V